Among patients who developed erythrocytosis while using SGLT-2 inhibitors, hematology consultations occurred in 18 (1.6%) patients, with median serum erythropoietin (EPO) levels of 12.5 mIU/mL (range 7.1–17.61 mIU/mL, reference 2.59–18.50 mIU/mL). Here, EPO is linked to polycythemia.